BiondVax Pharmaceuticals Ltd. (TASE:BNDX) has obtained approval of the ethics committees of the Hadassah Medical Organization in Jerusalem and the Sourasky Medical Center (Ichilov Hospital) in Tel Aviv to conduct a second Phase II clinical trial of the company's universal influenza vaccine. The trial will test the vaccine's efficacy and immune response.
The trial will include 120 male and female patients over the age of 65. Recruitment will begin immediately and the first inoculations are scheduled to be given in October. BiondVax expects to receive the trial results by the end of March 2011.
In June, BiondVax successfully completed a Phase II trial of its flu vaccine on people aged 18-49. That trial, which included 200 patients, met its safety and efficacy endpoints, improving the patients' immune response.
BiondVax's share price rose 7% in morning trading to NIS 1.53, giving a market cap of NIS 60 million.
Published by Globes [online], Israel business news - www.globes-online.com - on August 30, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011